SIGNA MAGNUS

The GE SIGNA MAGNUS is a dedicated 3.0T head-only magnetic resonance diagnostic device designed for high-resolution imaging of the head, neck, TMJ, and limited cervical spine. It leverages fundamental MRI principles with innovations like a specialized head-only gradient coil and optimized field-of-view, validated through extensive non-clinical and clinical testing to confirm its safety, effectiveness, and diagnostic performance.

The U.S. Food & Drug Administration has formally recognized GE Medical Systems, LLC's SIGNA MAGNUS as substantially equivalent to existing predicate devices, granting it clearance on October 17, 2024. This regulatory determination permits the marketing of the SIGNA MAGNUS as a Class II Magnetic Resonance Diagnostic Device, aligning it with established general controls and specific regulatory provisions for such medical equipment. The device is specifically designed for diagnostic imaging of the head, neck, temporomandibular joint (TMJ), and a limited section of the cervical spine in patients aged six years and older. The SIGNA MAGNUS operates as a 3.0T head-only magnetic resonance scanner, employing fundamental scientific principles akin to its predicate devices but incorporating several specialized features. These include a dedicated head-only gradient coil with high peak amplitude and slew rate, a distinct stepped patient bore, and a field-of-view meticulously optimized for its specific anatomical focus. Comprehensive non-clinical and clinical testing confirmed the system's safety and effectiveness, demonstrating diagnostic image performance that is comparable to its predicate device while adhering to various stringent safety and performance standards.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific clinical advantages does the SIGNA MAGNUS's specialized head-only design and enhanced gradient coil offer over general-purpose 3.0T MRI systems for neurological or head and neck diagnostics?; How does the unique stepped patient bore design influence patient experience, particularly concerning comfort, claustrophobia, or accessibility for diverse patient populations?; Could further detail be provided on the specific image quality metrics and clinical endpoints used during the non-clinical and clinical testing to establish comparable diagnostic performance to its predicate device?; What are the precise limitations or contraindications associated with the SIGNA MAGNUS, especially given its focused anatomical coverage and the specified minimum patient age of 6 years?; What potential future research or clinical applications are envisioned for this dedicated head-only MRI platform, particularly regarding advanced neuroimaging techniques or pediatric studies?